Renaissance Technologies
ENSC icon

Renaissance Technologies’s Ensysce Biosciences ENSC Stock Holding History

Renaissance Technologies’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,574
Closed -$36.9K – 3377
2025
Q3 		$36.9K Buy
+15,574
New +$33.5K ﹤0.01% 3379
2024
Q4 		– Sell
-1,493
Closed -$5.38K – 3659
2024
Q3 		$5.38K Buy
+1,493
New +$9.06K ﹤0.01% 3476
2024
Q2 		– Sell
-704
Closed -$8K – 3604
2024
Q1 		$8K Sell
704
-26
-4% -$413 ﹤0.01% 3634
2023
Q4 		$12K Buy
+730
New +$11.8K ﹤0.01% 3625
2022
Q3 		– Sell
-99
Closed -$309K – 4101
2022
Q2 		$309K Buy
99
+19
+24% +$53.2K ﹤0.01% 3440
2022
Q1 		$328K Buy
+80
New +$529K ﹤0.01% 3432

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

Renaissance Technologies's ENSC Position: Q4 2025 in Review

Renaissance Technologies sold out of Ensysce Biosciences (ENSC) in Q4 2025, closing a stake of 15,574 shares — an estimated $36.9K sold.

Renaissance Technologies first reported a position in ENSC in Q1 2022 and held it in 6 quarters. The position peaked at $328K in Q1 2022. 17 funds tracked by Wall St. Rank hold ENSC as of Q4 2025.

  • Renaissance Technologies reported no remaining Ensysce Biosciences position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 15,574 Ensysce Biosciences shares in Q4 2025, an estimated $36.9K.
  • Renaissance Technologies first reported a position in Ensysce Biosciences in Q1 2022 and held it in 6 quarters.
  • Renaissance Technologies's Ensysce Biosciences position peaked at $328K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.